Innovative cancer therapies designed to reactivate a patients own immune cells to attack their tumors has revolutionized cancer treatment and is saving many lives. Department of Pathology & Molecular Medicine MD-PhD student Dr. Brian Laight and colleagues working from the Sinclair Cancer Research Institute report in the journal Cancer Research that immune therapies which stimulate cytotoxic T lymphocytes to attack cancer could be made even more effective by stimulating another class of immune cells called dendritic cells - which are responsible for alerting the T lymphocytes to the presence of the tumor and activating them to kill cancer cells. The combined targeting of these two types of immune cells holds promise to further improve survival in multiple cancer types.